Search - tctmd.com

Displaying 601 - 620 of 906

Sort: Relevancy | Date

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

News Conference News

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

April 07, 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

March 27, 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

News Conference News ACC 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

March 22, 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

March 19, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

Live From Washington: ACC 2017, Day Two

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

March 18, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

March 17, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Does It Matter How Clot is Removed in Acute Ischemic Stroke? Maybe Not

News Conference News ISC 2017

Does It Matter How Clot Is Removed in Acute Ischemic Stroke? Maybe Not

February 22, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

News Conference News ISET 2017

Gains in Carotid Stenting Technology Could Increase the Treatment’s Appeal

February 13, 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

February 07, 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

News Conference News ISET 2017

Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients

February 06, 2017

News Conference News AHA 2016

“Huge Shift” Favoring Interventions in Aortic Stenosis Care May Still Omit Many Elderly Patients

Yael L. Maxwell

November 21, 2016

News Conference News AHA 2016

Subclinical A-fib Common in Older, Asymptomatic Patients

November 18, 2016

News Conference News AHA 2016

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

November 16, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.